2.1 Patients and data collection
This single-center prospective study was conducted between June 2019 and
September 2020 at the First Affiliated Hospital of Guangxi Medical
University, Guangxi, China. We enrolled patients aged <18
years with malignant hematological diseases who received voriconazole
intravenously or orally for the prevention or treatment of IFI. The
initial dose of voriconazole was administered in accordance with the
drug label or the clinician’s experience, and adjusted according to the
patient’s clinical response. The exclusion criteria were: (1)
voriconazole failed to reach the steady-state described in the
guidelines20or was replaced with other antifungal
agents during the treatment; (2) undergoing hemodialysis or
hemofiltration; (3) allergic to voriconazole.
The following information for patients enrolled are collected:
demographics data [gender, age, weight, and body surface area (BSA)
etc], laboratory test data [white blood cell count (WBC), neutrophil
absolute value (NEU), hemoglobin (HGB), platelet count (PLT), total
bilirubin (TBIL), aspartate transaminase (AST), alanine aminotransferase
(ALT), gamma glutamyl transpeptidase (GGT),Albumin (ALB), alkaline
phosphatase (ALP), creatinine (SCR), cystatin C (CYSC), endogenous
creatinine clearance (Ccr)] and the concomitant drugs taken during VRC
therapy [proton pump inhibitors (PPIs), including omeprazole,
esomeprazole, pantoprazole, lansoprazole and rabeprazole, glucocorticoid
(GLU), including dexamethasone and prednisone].